RSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease among infants and young children worldwide, especially in low- and middle-income countries (LMICs). RSM01 is a novel, highly potent, half-life-extended anti-RSV monoclonal antibody (mAb) candi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Aurelio Bonavia, Micha Levi, Harald Rouha, Adriana Badarau, Jonne Terstappen, Shayne Watson, Aparna B. Anderson, Joleen T. White, Jintanat Ananworanich, Dale Taylor, Andrijana Radivojevic, Michael Shaffer, Luisa M. Stamm, Michael W. Dunne
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-12-01
Colecção:	BMC Infectious Diseases
Assuntos:	RSV Lower respiratory tract infection Monoclonal antibody LMIC Infants Children
Acesso em linha:	https://doi.org/10.1186/s12879-024-10120-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!